SCHEMBL5458963

SCHEMBL5458963

COc1ccc(CNC(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 9/20 0.71
MAPT P10636 2/20 0.64
RXFP1 Q9HBX9 1/20 0.62
KMT2A Q03164 5/20 0.59
MEN1 O00255 4/20 0.59
THRB P10828 1/20 0.59
MGAM O43451 2/20 0.58
AMY1A P0DUB6 1/20 0.58
RAB9A P51151 1/20 0.58
ALDH1A1 P00352 1/20 0.58
HPGD P15428 1/20 0.58
ALOX15 P16050 1/20 0.58
TSHR P16473 1/20 0.58
HSD17B10 Q99714 1/20 0.58
GLO1 Q04760 1/20 0.56
RECQL P46063 1/20 0.56
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5454158 0.88 FLT3 (0.68) FLT3MAPTKMT2AMEN1RAB9A
SCHEMBL5455744 0.88 FLT3 (0.56) FLT3MAPTRXFP1KMT2AMEN1
SCHEMBL5458411 0.87 CFTR (0.55) FLT3MAPTRXFP1KMT2AMEN1
SCHEMBL5453363 0.87 FLT3 (0.71) FLT3MAPTKMT2AMEN1MGAM
SCHEMBL5455906 0.86 FLT3 (0.74) FLT3MAPTRXFP1KMT2AMEN1
SCHEMBL5460296 0.85 FLT3 (0.80) FLT3MAPTRXFP1KMT2AMEN1
SCHEMBL5460444 0.82 KMT2A (0.78) FLT3KMT2AMEN1MGAMRAB9A
SCHEMBL5459776 0.81 FLT3 (0.66) FLT3MAPTRXFP1KMT2AMEN1
SCHEMBL5466107 0.80 FLT3 (0.64) FLT3MAPTKMT2AMEN1RAB9A
SCHEMBL5455677 0.79 FLT3 (0.74) FLT3MAPTRXFP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MAPT 21/4885RXFP1 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.